A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions
Status:
Completed
Trial end date:
2014-09-08
Target enrollment:
Participant gender:
Summary
This study evaluates pharmacokinetics of eltrombopag 50 mg after the oral administration in
Mexican healthy volunteers under fasting conditions. The study will be an open label, single
dose study with 26 subjects planned to be enrolled. Healthy subjects (male and female) aged
between 18 - 50 years of age (inclusive) and a Body Mass Index within the range of 18-27.0
kg/meter (m)^2 (inclusive) were enrolled according to Quetelet. REVOLADE is a registered
trademark of the GSK group of companies.